Compassionate Use Program at Medicity to Commence

Zacks Small Cap Research

By Brian Marckx, CFA

Aethlon Medical (OTC BB:AEMD)
announced yesterday (12/3/2012) that they have initiated a compassionate use program at the Medicity Institute in India using Hemopurifier therapy in the treatment of HCV.  As a reminder, earlier this year the Medicity IRB approved use of Hemopurifier in a compassionate use program and in early October AEMD announced the protocol that will govern treatment under this program.

With the initiation of treatment under compassionate use, this will mark AEMD's initial foray into commercialization of Hemopurifier.  Yesterday's press release details the treatment pricing ($7,235 for 3-day treatment, $2,295 each add'l day) and reiterates the previously announced protocol and inclusion/exclusion criteria. 

As we've noted in earlier investor notes, the compassionate use program should provide AEMD with another revenue stream (albeit likely minimal, particularly at the outset) and potentially more importantly, will increase the overall patient experience and treatment volume which could bode well for increasing awareness of Hemopurifier therapy and further bolster credibility of the technology.

Treatment under this program is open to patients worldwide and could potentially draw individuals from outside of India, including the U.S. and Europe - AEMD notes Medicity is a leading center for medical tourism. 

For a free copy of the AEMD research report or additional research on other small-cap stocks, please visit scr.zacks.com.

To become a subscriber to Zacks SCR and receive SCR blogs and research reports emailed directly to your inbox, please visit our Subscribe page.

Rates

View Comments (0)